Monoclonal antibodies against pneumococcal surface protein A (PspA) have been shown to protect mice from fatal pneumococcal infection. PspA is highly variable serologically, raising the possibility that PspA from one strain might not be able to elicit protective responses against strains which possess serologically different PspA. We have prepared a Agtll library of pneumococcal genomic DNA and identified a clone expressing PspA. The recombinant PspA in this phage lysate elicited protection against pnehmococcal infections with three strains of two different capsular serotypes. This finding demonstrated that PspA could elicit a protective response in the absence of other pneumococcal antigens. The observed protection was probably antibody mediated because it could be passively transferred with immune sera. Lambda lysates producing pneumococcal proteins other than PspA failed to elicit protection against fatal pneumococcal infection.
It is well established that immunity to Streptococcus pneumoniae can be mediated by specific antibodies against the polysaccharide capsule of the pneumococcus (16) . Immunization of persons over 65 years of age with capsular polysaccharide results in protection, with an efficacy of about 60% (3) . Unfortunately, neonates and young children fail to develop an immune response against polysaccharide antigens (1, 7, 9, 14) , are not effectively immunized with the polysaccharide pneumococcal vaccine, and can have repeated infections involving the same capsular serotype (10) .
Young children have been immunized against Haemophilus influenzae, another encapsulated bacterium, by conjugating the capsular polysaccharide to proteins to make it immunogenic (13) . However, there are over 80 known capsular serotypes of S. pneumoniae, of which 23 account for most of the disease. For a pneumococcal polysaccharideprotein conjugate vaccine to be successful, the capsular types responsible for most pneumococcal infections would have to be made adequately immunogenic.
An alternative approach to protecting children from pneumococcal infections would be to identify protein antigens that could elicit protective immune responses. Such proteins might serve as a vaccine by themselves but more likely could be used in conjunction with successful polysaccharide-protein conjugates or as carriers for polysaccharides. Such T-cell-dependent vaccines might also be beneficial for the elderly.
In previous studies, we have shown that monoclonal antibodies to PspA (pneumococcal surface protein A) are able to protect mice from fatal pneumococcal infection (18, 20) . We have also shown that immunization of X-linked immunodeficient (XID) mice with nonencapsulated pneumococci expressing PspA will protect mice from subsequent fatal infection with pneumococci but that immunization with isogenic pneumococci lacking PspA will not (23) .
No other pneumococcal protein has been identified that can protect mice from fatal infection with pneumococci, * Corresponding author.
although immunizations with both pneumolysin and neuraminidase result in a statistically significant delay to time of death when mice are infected with a normally lethal dose of pneumococci (15, 25) . In our attempts to make antibodies to pneumococcal surface proteins by immunizing with whole pneumococci or pneumococcal cell wall extracts (CWEs), we have observed that over half of the antiprotein monoclbnal antibodies produced are to PspA (8, 20) . Of a panel of 9 anti-PspA monoclonal antibodies, we found 6 to be protective (3a, 20) . Ten In this study we have prepared a Agtll pneumococcal genomic DNA library to search for cloned genes producing protection-eliciting antigens. Clones producing PspA and other pneumococcal antigens were tested to see whether they could elicit protection against fatal pneumococcal infection with strains of pneumococci virulent in mice.
MATERIALS AND METHODS
Mice. CBA/N (xid) mice were obtained from the Jackson Laboratory, Bar Harbor, Maine. These mice carry the XID trait, which renders them virtually unable to respond to polysaccharide antigens, but they do respond with normal levels of antibodies against protein antigens (29) .
Bacterial strains and growth conditions. S. pneumoniae strains included type 2 strain D39 (2), type 3 strains WU2 (6) and A66 (2) , type 6A strain EF-6796 (obtained courtesy of Catharina Svanborg-Eden, University of Goteborg, Goteborg, Sweden), and the nonencapsulated strains Rxl (27) and WG44.1 (23) . WG44.1 was a mutant of Rxl that failed to express PspA, while all other strains were PspA+. The 50% lethal doses (LD50s) of D39, WU2, A66, and EF-6796 in XID mice have all been determined to be between 1 and 10 CFU (4).
All strains were maintained as frozen stocks in 10% glycerol at -80°C. Pneumococcal cultures were grown ac-RECOMBINANT PspA ELICITS PROTECTIVE IMMUNITY cording to procedures routinely used in our laboratory (17) and harvested by centrifugation (4,000 x g, 10 min). The CFU of pneumococci were determined by plating on blood agar. Escherichia coli cultures were grown in LB medium (26) or LB supplemented with 10 mM MgSO4.
Monoclonal antibodies. All hybridoma cell lines secreting antibody were obtained from fusions with the myeloma P3-X63-Ag8.653 (12, 20) . Monoclonal antibodies used in this study included antibodies to PspA, Xi64 (immunoglobulin M), and Xi126 (immunoglobulin G2b), which have previously been shown to protect mice against pneumococcal infection (20, 21) , as well as additional antibodies produced in this study by using methods previously described (20) . Monoclonal antibodies were used as unfractionated tissue culture supernatants for detection of PspA or as diluted ascites in protection experiments as previously described (17, 22) .
Rabbit immunization. A rabbit antiserum reactive with non-PspA pneumococcal surface components was prepared by immunizing a rabbit with CWE from pneumococcal strain WG44.1. CWE was prepared as previously described (21), diluted to 1.0 mg of total protein per ml with Ringer's lactate, mixed 1:1 with complete Freund adjuvant (CFA), and injected subcutaneously. Booster injections were given every 2 weeks without adjuvant. The rabbit was bled monthly, and the serum was examined for reactivity with pneumococcal proteins in an immunoblot of WG44.1 CWE. When reactivity was detected at a dilution of greater than 1/30,000, 40 ml of serum was collected, aliquoted, and stored at -20°C.
Library construction and screening. A genomic DNA library was prepared in the phage vector Xgtll by using DNA from pneumococcal type 2 strain D39. High-molecularweight DNA was isolated from D39 as previously described (23) . The library was constructed according to the protocols of Huynh, Young, and Davis (11) . The D39 DNA was mechanically sheared to produce fragments between 0.5 and 7.0 kb. The fragments were treated with EcoRI methylase, the ends were filled in with Klenow fragment, and EcoRI linkers were added. The sample was cut with EcoRI and size fractionated to isolate fragments greater than 0.5 kb. The fragments were ligated into Xgtll arms, packaged, and infected into E. coli Y1088.
Screening of clones reactive with anti-PspA monoclonal antibodies or the rabbit antiserum was performed by infecting E. coli Y1090 cells with the Agtll D39 genomic library (approximately 2 x 103 plaques per plate) at 42°C for 3.5 h (31) . The plates were overlaid with nitrocellulose filters previously soaked in 10 mM isopropyl-,3-D-thiogalactopyranoside (IPTG) and incubated overnight at 370C. The filters were removed from the plates and incubated in a blocking solution of 1% bovine serum albumin (BSA) in phosphatebuffered saline (PBS) at room temperature for 1 h. The filters were then incubated at room temperature with either Xi64, Xi126 (each diluted 1/10), or the rabbit antiserum (1/15,000 dilution). The filters were then sequentially incubated with biotinylated goat anti-mouse or goat anti-rabbit immunoglobulin (0.2 ,ug/ml) (Southern Biotechnology Associates, Inc., Birmingham, Ala.) and streptavidin peroxidase (Southern Biotechnology Associates) with washes between each step with PBS plus 0.05% Tween 20. After a final wash with PBS plus 0.05% Tween 20, the filters were incubated with the peroxidase substrate 4-chloro-1-naphthol until the color was fully developed (approximately 30 min). Plaques 30 ,ug of total proteins (Bio-Rad protein assay; Bio-Rad Laboratories, Richmond, Calif.) were electrophoresed through a 9% resolving gel using a Mini-Protean II gel system (Bio-Rad). The electrophoresed proteins were transferred to nitrocellulose by using the Mini-Trans-Blot system (Bio-Rad) at 100 V (250 mA) for 1 h in a 25 mM Tris-192 mM glycine-20% methanol buffer (pH 8.3). The membrane was processed as described above for the plaque screening, except that streptavidin alkaline phosphatase was used and the antibody-reactive bands were visualized by incubating the membrane in a 0.5-mg/ml solution of 5-bromo-4-chloro-3-indolyl phosphate (Sigma) in 1 M Tris (pH 8.8) with 0.01% Nitro Blue Tetrazolium (Sigma).
Southern blot analysis. DNA hybridization was carried out on DNA fragments transferred to nitrocellulose by the method of Southern (28) as previously described (23), except that hybridized fragments were detected by using the BluGENE nonradioactive system (Bethesda Research Laboratories, Gaithersburg, Md.). The probe used in these studies was pKSD300 (23) , which contains a 550-bp insert of pneumococcal DNA from pspA. The pKSD300 probe was biotin labeled by following the instructions of the Bethesda Research Laboratories nick translation kit and by using biotin-11-dUTP. After hybridization, the blots were processed by following the instructions of the Bethesda Research Laboratories BluGENE kit.
Mouse immunization studies. In initial studies, XID mice were immunized either with lysates producing PspA or with 1 of 19 pools of lysates that reacted with the rabbit antiserum. Mice were immunized by subcutaneous injection in the subinguinal area with antigen emulsified in CFA. After 14 days, the mice were injected intraperitoneally with antigen preps diluted in Ringer's lactate without CFA. Seven days later, the mice were challenged intravenously with about 600 times the LD50 of pneumococcal strain WU2. The survival of the mice was monitored for 10 days. In experiments to assess cross-protection elicited by recombinant PspA, mice were challenged with at least 300 times the LD50 of infecting pneumococci.
The relative quantity of PspA in phage lysates used for immunization was determined by using a previously described enzyme-linked immunosorbent assay (ELISA) inhibition procedure (20) . In this assay, phage lysates containing recombinant PspA were tested for their ability to block the binding of Xi126 to heat-killed Rxl. Experiments had shown that two injections of pneumococcal CWE containing 20 ,ug of total protein had sufficient PspA to elicit protection in mice against pneumococcal challenge. Therefore, a dilution of phage lysate that resulted in inhibition of Xi126 binding equivalent to that obtained by 20,ug of CWE was designated as 1 unit of PspA. As a control for the mouse immunization studies, we selected a recombinant Xgtll clone from the library that contained an apparent insert of pneumococcal DNA but failed to produce any protein detectable by anti-PspA antibodies. One unit of the control lysate was defined as the dilution, determined on the basis of PFU per milliliter, that corresponded to 1 U of the lysate producing full-length PspA.
In the experiments in which pooled lysates were used to immunize mice, the pools contained 5 to 12 individually isolated phage lysates. Each pool was prepared by adding 50 ,ul of the individual lysates to Ringer's lactate to give a final volume of 1.0 ml. This was mixed 1:1 with CFA prior to injection. As a positive control for these pools of non-PspA producing clones, a pool was prepared which was composed of equal volumes of lysate from 11 non-PspA-producing clones and from the clone producing full-length PspA.
Anti-PspA response of immunized mice. A direct binding ELISA was used to estimate the amount of anti-PspA antibody in the sera of mice immunized with recombinant PspA. After coating microtitration plates with heat-killed Rxl and blocking with 1% BSA, either mouse sera or quantitated purified Xi126, which served as a standard, was diluted in duplicate through seven wells. The assay was then developed in a typical fashion, and the bound antibody was detected with goat anti-mouse immunoglobulin alkaline phosphatase-conjugated antiserum (Southern Biotechnology Associates). The dilution of each serum sample giving 33% maximum binding with respect to Xi126 was determined, and on the basis of the dilution of Xi126 that gave 33% binding, the results for the individual mouse sera were expressed (in micrograms per milliliter) (5). As a specificity control for binding to non-PspA antigens, other plates were coated with heat-killed WG44.1, which has a deletion in the upstream portion of pspA (29a) and fails to produce detectable PspA (23) .
RESULTS
Isolation and characterization of PspA+ and PspA-clones. The Agtll genomic DNA library from pneumococcal strain D39 was screened with the PspA-binding monoclonal antibody Xi126 and with a rabbit serum against WG44.1 CWE. The rabbit antiserum was used in an effort to detect clones producing non-PspA pneumococcal proteins. Since WG44.1 is a mutant of Rxl (a nonencapsulated variant derived from D39) that fails to produce PspA, the proteins detected by the rabbit antiserum would not be expected to include PspA.
Two clones reactive with Xi126 were detected from a total of 1.5 x 104 phage tested. One clone was found to contain an insert of 3.8 kb of pneumococcal DNA and produced fulllength PspA (84 kDa) (Fig. 1 ). The other clone had an insert of 2.9 kb of pneumococcal DNA and encoded a molecule with an apparent molecular mass of 47 kDa. There were two additional lower-molecular-mass bands, 42 and 38 kDa, produced by this clone which may be breakdown products of the 47-kDa band.
An immunoblot of the Xi126-reactive phage lysates revealed several features of the antibody-reactive molecules (Fig. 1) . The full-length clone gave a banding pattern almost identical to that of PspA from pneumococcal strain D39. Both the full-length and partial clones produced PspA independent of induction by IPTG, indicating that expression is occurring from the pspA promoter. Finally, epitopes detected by protective monoclonal antibodies Xi64 and Xi126, which react with different PspA epitopes (20) , are present on PspA produced in E. coli. The banding pattern with Xi64 was identical to that seen with Xi126 in Fig. 1 (data not shown) . The observation that PspA was expressed as a non-,Bgalactosidase fusion protein has been seen with other proteins expressed in Xgtll (24, 30) .
PspA+ pneumococcal DNA inserts were characterized by restriction mapping (Fig. 2) and Southern blot analysis. The Southern blots of the Xgtll inserts were carried out by using a previously cloned 550-bp fragment of pspA (23) .
In an effort to clone protection-eliciting non-PspA proteins, we cally significant protection, but three of six mice did survive when immunized with the higher dose of the partial clone. Mice immunized with an equivalent or even a 10-fold excess of lysate from a PspA-clone were not protected from infection with pneumococci, providing evidence that the protection seen with the PspA+ clones was not due to injection of E. coli antigens. The data are a composite of two similar experiments. The protection-eliciting effects of PspA against 300 times the LD50 of WU2 were also apparent when it was present as only 1 of a pool of 12 lysates from Agtll clones ( Table 2) .
To determine the relative protection-eliciting ability of PspA compared with other pneumococcal proteins, mice were immunized with the 139 lambda lysates that produced non-PspA pneumococcal antigens. Lysates prepared from the 139 stable clones were used to form 19 pools, and each pool was used to immunize groups of three XID mice which were subsequently challenged with 300 times the LD50 of type 3 strain WU2. Because of this small sample size, we did not expect to see statistically significant protection even if all three injected mice survived. Since any pool that protected all three mice would be studied further, we expected this procedure to identify any pool that contained a clone producing a protection-eliciting antigen.
To make sure that it was possible to detect a highly immunogenic clone capable of eliciting protection, even as part of a pool, XID mice were immunized with a mixture containing both 11 non-PspA-producing lysates that had previously been shown not to elicit protection and phage lysate from the recombinant PspA clone. This pool of 12 lysates, 1 of which produced full-length recombinant PspA, protected five of five mice. None of five mice injected with the same pool lacking recombinant PspA lysate survived.
Of the 57 mice vaccinated with the other pools of nonPspA lysates, only 14 mice survived to the end of the experiment at 10 days postchallenge. However, in 1 of the 19 pools (group 3), all three mice survived to 10 days postchallenge (Table 2) . To determine if group 3 might contain an effective protection-eliciting clone, each of the 5 lysates that made up group 3 were injected separately into groups of 8 to 17 XID mice. As a control, 21 XID mice were immunized with the PspA-clone that previously did not elicit protection. The immunized mice were challenged with 600 times the LD50 and monitored for 10 days. None of the clones (8, 23) . In fact, PspA of strain EF-6796 was unreactive with the anti-PspA antibodies Xi64 and Xi126 (data not shown). The observation that recombinant D39 PspA elicited protection against EF-6796 indicated that D39 PspA contained protection-eliciting epitopes other than those recognized by the monoclonal antibodies Xi64 and Xi126.
Antibody elicited by recombinant PspA. By using a direct binding ELISA, we examined the antibody response to PspA of the mice immunized with the recombinant PspA clones (Fig. 3) . The elicited response appeared to be specific for PspA, since no increase above background levels of binding was detected when the sera were reacted with the PspApneumococcal strain WG44.1. When sera from the mice immunized with recombinant PspA were used in an immunoblot against CWE of the encapsulated strain D39, the same bands were detected by the mouse sera and by Xi126 (data not shown).
Immunity elicited to the recombinant PspA could be passively transferred with serum. Unimmunized XID mice were given 162 ,ug of anti-PspA antibody per mouse, as determined by ELISA, by passively transferring sera from XID mice immunized with recombinant PspA. Five of five XID mice that received immune sera were protected from 55 CFU of WU2, while five mice that received sera from nonimmunized mice died.
An additional demonstration of anti-PspA specificity of the elicited antibody came from an examination of the specificity of hybridoma antibodies produced by fusion of splenic lymphocytes from two mice immunized with the full-length recombinant PspA. Each of the 16 hybridomas that secreted antibodies reactive with D39 detected PspA, as evidenced by immunoblotting in parallel with lanes developed with Xi126. All 16 antibodies reacted with the partial PspA clone that expresses the amino-terminal portion of PspA. Eleven of the 16 antibodies were tested for their ability to protect mice from infection with 300 CFU of WU2. Antibodies XiR278, XiR1323, XiR1325, and XiR1526 were found to protect mice from fatal pneumococcal infection.
DISCUSSION
In previous studies we demonstrated that heat-killed nonencapsulated PspA+ pneumococci in Ringer's lactate solution injected intravenously elicited protective immunity in XID mice but that isogenic PspA-pneumococci did not (23) . This was taken as evidence that PspA could elicit protection. However, the immunizing pneumococci may have carried other antigens capable of eliciting responses that contributed to the protective effect of injection with the PspA+ strain. Our present observation that immunization with recombinant PspA can increase the LD50 to pneumococcal infection by at least 5 logs provides a solid demonstration that PspA in the absence of other pneumococcal antigens can elicit protection.
These studies also demonstrate that recombinant PspA cloned from strain D39 is able to elicit cross-protection against three pneumococcal isolates of two different serotypes. This indicates that, unlike the capsule polysaccharide vaccine, immunization with a single PspA will be able to provide protection against strains of more than one capsular type. It is significant, in this regard, that protection was elicited against strain EF-6796, which lacks the distinct epitopes detected by protective monoclonal antibodies Xi64 and Xi126 (20, 23) . Therefore, additional protection-eliciting epitopes not detected by these antibodies must be present on PspA from strain D39.
We observed that the protective monoclonal antibodies Xi64 and Xi126, which recognize different epitopes (20) , reacted with recombinant PspA from both clones in an immunoblot. These antibodies also reacted with PspA produced by the partial clone, indicating that protection-eliciting epitopes reside in this amino-terminal portion of the molecule. The failure of the partial clone to elicit protection, even though it reacts with two protection-conferring anti- Recombinant PspA cloned from strain D39 was unable to elicit protection against strain D39, even though it did elicit protection against type 3 and type 6A strains. Mice immunized with recombinant PspA and challenged with D39 survived longer than control mice, but this increased survival was not statistically significant. In previous studies, we found that protection against D39 required far more Xi126 than protection against other pneumococcal isolates did (20) . Therefore, it appears that D39 may differ from the other pneumococcal isolates in its resistance to anti-PspA-mediated protection. The poor protection against D39 is consistent with experiments in which PspA-mutants of D39 have been produced. The insertional inactivation of pspA in D39 results in a rapid initial decrease of pneumococci in the blood of mice during the first hour postinjection. However, the bacteria are apparently able to compensate for the lack of PspA and ultimately go on to kill the mice (23) . This result with D39 stands in contrast to the results of a similar study with PspA-WU2 in which the loss of PspA resulted in a total loss of virulence (29a).
Our approach to identifying other protection-eliciting molecules of D39 was based on the use of a rabbit antiserum to cell wall components prepared from a PspA-mutant of the nonencapsulated D39 variant, Rxl. This strain was chosen for immunization because preliminary data (unpublished observation) demonstrated that CWE from this strain could elicit protective immunity to pneumococci when injected with adjuvant into XID mice. Since we already knew that PspA was an immunodominant antigen of pneumococci, we expected that by using a PspA-derivative we would favor the production of an antiserum to non-PspA proteins. Since none of the non-PspA clones elicited protection comparable to that of PspA, our findings emphasize the special ability of PspA to elicit protection against pneumococcal infection.
